icon-folder.gif   Conference Reports for NATAP  
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
Dual Oral Combination Therapy with the NS5A Inhibitor Daclatasvir(DCV; BMS-790052) and the NS3 Protease Inhibitor Asunaprevir(ASV; BMS-650032) Achieved 90% Sustained Virologic Response (SVR12) in Japanese HCV Genotype 1b-Infected Null Responders
  Reported by Jules Levin
AASLD No 5-9 2011 SF

K Chayama,S Takahashi, Y Kawakami, K Ikeda, F Suzuki, J Toyota,Y Karino,T Ohmura, H Ishikawa, H Watanabe, T Guo,F McPhee, EA Hughes, H Kumada

Dual oral therapy with daclatasvirand asunaprevirprovided rapid and persistent viral suppression in null responders with genotype 1b infection

- All patients who completed 24 weeks' treatment achieved SVR24

- HCV RNA also undetectable 24 weeks post-treatment in patient who discontinued after only 2 weeks

No apparent association between baseline resistance polymorphisms and virologic outcome

Daclatasvir+ asunaprevircombination was generally well tolerated

- Adverse event profile compares favorably with historical experience withpeg-alfa/RBV

High cure rates are possible with dual oral DAA therapy in patients with genotype 1b infection


peg-alfa/RBV, peginterferon alfa + ribavirin; SVR, sustained virologic response.

1. PoynardT, et al. Gastroenterology 2009;136:1618-1628;
2. Jensen DM, et al. Ann Intern Med 2009;150:528-540;
3. Zeuzem S, et al. N Engl J Med 2011;364:2417-2428;
4. Bacon BR, et al. N Engl J Med 2011;364:1207-1217;
5. GaoM, et al. Nature2010;465:96-100;
6. McPhee F, et al. J Hepatol2010;52(suppl1):S296;
7. BronowickiJP, et al. J Hepatol 2011;54(suppl1):S472;
8. Lok A, et al. J Hepatol 2011;54(suppl1):S536.

ClinicalTrials.gov identifier NCT01051414.

cEVR, complete early virologic response; EOTR, end of treatment response; eRVR, extended rapid virologic response; IFN, interferon; RVR, rapid virologic response.

1. Bronowicki JP, et al. J Hepatol 2011;54(suppl 1):S472.